machmit schreef op 18 mei 2016 15:40:
[...]
16 mrt. 2015 - NEW YORK (GenomeWeb) – Illumina and its wholly-owned subsidiary Verinata Health have filed a patent infringement suit against Premaitha ... Illumina (Nasdaq: ILMN) announced that it and its wholly-owned subsidiary, Verinata Health Inc., (together “Illumina”) have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom.
Illumina Patent Infringement Proceedings Update. Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular ... Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal testing (NIPT) has been informed that Illumina, Inc. has today added a third patent to the two previously asserted in a UK patent suit against Premaitha in the High Court of Justice, Chancery Division, Patents Court in the UK.
The patent asserted in this filing is EP2183693.
The Directors believe that the IONA® test does not infringe these patents as claimed by Illumina and the alleged infringement is unfounded.
-Ends-
8 jan. 2016 - Premaitha continues to make a robust defence against earlier claims by Illumina and the Board is confident that the IONA® test does not ... Manchester, UK – 8 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, notes that Illumina, Inc. has today announced two patent infringement suits in Europe, one of which is against Premaitha’s customer in Poland. Illumina has also today taken similar action against Ariosa Diagnostics, a subsidiary of Roche, and their customer, The Doctors Laboratory, in the UK.
Premaitha continues to make a robust defence against earlier claims by Illumina and the Board is confident that the IONA® test does not infringe the patents as claimed in the earlier cases or in relation to today’s announcement.
Dr Stephen Little, CEO of Premaitha said: “These lawsuits are a continuation of attempts by Illumina to restrict competition in the European NIPT market. We believe pregnant women should not be denied choice in their decisions for prenatal care. Despite these distractions, we have made strong progress with our best-in-class IONA® test. We will support our customers against such actions and we look forward to announcing new contract wins in new international territories in the near future.”
-Ends-
26 jan. 2016 - No date has currently been set for the proceedings of the second claim lodged by Illumina in October 2015. The Company understands these ... Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines involved in the UK litigation previously lodged by Illumina.
The Company has been advised that a date has now been set for the High Court to hear the first claim lodged by Illumina in March 2015. These proceedings will take place in early October 2016 and the outcome is likely to be known by Christmas 2016, subject to any appeals.
No date has currently been set for the proceedings of the second claim lodged by Illumina in October 2015. The Company understands these will not be before 1 January 2017.
Dr Stephen Little, CEO, Premaitha commented: “We fully understand that investors are keen for clarification on how the legal process in the UK will unfold. Therefore, as we have done today, we will continue to update investors as and when possible even though the process is inherently complex, timelines uncertain and much detailed information must by necessity remain confidential.
“We continue to defend these actions robustly and we remain focused on delivering patient choice through high quality non-invasive prenatal testing in the UK and internationally."
- Ends -